Trusted Resource for Clinical Trials, Protocols & Progress
External audits are assessments performed by entities outside of the clinical trial site or sponsor’s QA department. These audits evaluate trial conduct, documentation, and data integrity to ensure compliance with GCP, ethical standards, and regulatory requirements. They can be conducted by sponsors, regulatory authorities, CROs, or other independent third parties.
Click to read the full article.
Audits conducted by sponsors or Contract Research Organizations (CROs) are designed to assess a site’s compliance with Good Clinical Practice (GCP), protocol adherence, and readiness for regulatory inspections. These audits are not punitive—they are quality assurance tools that ensure reliable trial data, subject safety, and proper documentation of trial activities.
Click to read the full article.
Regulatory authority audits—also referred to as inspections—are formal evaluations conducted by national or regional agencies such as the FDA, EMA, MHRA, or CDSCO. Their objective is to verify the integrity of trial data, assess GCP compliance, and ensure subject safety. Hosting such an audit requires precise planning and a calm, organized approach.
Click to read the full article.
External audits—whether regulatory or sponsor-conducted—typically conclude with a detailed report outlining observations. These findings are classified into categories that guide the urgency and depth of the response:
Click to read the full article.
In modern clinical trials, outsourcing is inevitable—be it to CROs, central labs, IVRS providers, or eTMF vendors. While outsourcing can improve efficiency, sponsors and QA teams retain the ultimate regulatory responsibility. Hence, managing vendor and third-party audits is crucial to ensure GxP compliance and trial integrity.
Click to read the full article.
Clinical research sites play a critical role in ensuring GCP-compliant execution of trials. When external QA inspections—be it sponsor audits, CRO evaluations, or regulatory authority visits—occur, site staff are on the front line. For many investigators and coordinators, such inspections can be stressful. However, with proper preparation and awareness, these visits can be turned into opportunities to showcase site quality systems.
Click to read the full article.
External audits are a routine but critical part of pharmaceutical quality systems. When findings arise during sponsor, CRO, or regulatory inspections, a structured and compliant response is expected. The Corrective and Preventive Action (CAPA) system forms the backbone of this response framework. A well-documented, timely, and justified CAPA not only addresses the audit observation but also assures regulators and stakeholders that the issue is understood, contained, and unlikely to recur.
Click to read the full article.
In clinical research, the terms “audit” and “inspection” are often used interchangeably. However, for sponsors, investigators, and QA professionals, distinguishing between an external audit and a regulatory inspection is critical. Each carries different objectives, authorities, consequences, and documentation standards.
Click to read the full article.
Clinical trials are subject to both internal and external audits at any time during the study lifecycle. However, audit preparation is often treated as a last-minute scramble rather than an embedded cultural practice. A truly audit-ready site or team operates as though an auditor could walk in any day — and everything would be in order.
Click to read the full article.
External audits are critical checkpoints that evaluate compliance with GCP, sponsor expectations, and regulatory frameworks. A failed audit — especially when resulting in major or critical findings — can have serious consequences including study hold, sponsor termination, or regulatory action.
Click to read the full article.
